Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pirfenidone (PFD)
Pirfenidone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | placebo |
| Pirfenidone | DRUG | pirfenidone 801 mg TID |
| Deupirfenidone | DRUG | Deupirfenidone |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
Pirfenidone is an investigational small molecule being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Pirfenidone is being developed by PureTech Health plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol PRTC. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Idiopathic Pulmonary Fibrosis.
Pirfenidone is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies such as the FDA. The ongoing Phase 2 trial is actively enrolling participants to assess the treatment's effects in Idiopathic Pulmonary Fibrosis.
Pirfenidone is being evaluated in a Phase 2 clinical trial registered as NCT05321420, titled "LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)." This active, non-recruiting study has an enrollment target of 240 participants and is investigating the drug's use in Idiopathic Pulmonary Fibrosis.
Pirfenidone is also known as Pirfenidone (PFD). The clinical trial NCT05321420 refers to the drug as LYT-100, which appears to be an alternative name used in the study context. Both names refer to the same investigational small molecule being developed for Idiopathic Pulmonary Fibrosis.